AST-0555

AST-0555 is a small molecule drug in the discovery phase, developed by Aston SCI. It acts as an inhibitor of three related kinases involved in cellular stress response and protein synthesis regulation: eukaryotic translation initiation factor 2 alpha kinase 1 (EIF2AK1), eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4), and protein kinase R-like endoplasmic reticulum kinase (PERK, also known as EIF2AK3). By inhibiting these kinases, AST-0555 may modulate pathways relevant to diseases such as neoplasms, congenital disorders, and digestive system disorders. Its primary indications under investigation include sickle cell anemia, pancreatic ductal adenocarcinoma, and sarcoma[1].